Skip to main content
. 2023 Jan 30;14:1055671. doi: 10.3389/fimmu.2023.1055671

Figure 5.

Figure 5

DSP-0509 in combination with anti-CTLA-4 antibody significantly enhanced anti-tumor activity (A) CT26 tumor was inoculated subcutaneously into the dorsal flanks of Balb/c mice on day 0. 5 mg/kg of DSP-0509 was administered intravenously on days 7, 14, and 21. 200 μg/mouse of anti-CTLA4 antibody (9F10) was administered intraperitoneally on days 7, 9, 14, 16, and 20. Tumor volume is the mean ± S.E.M. of each group (n=6/group). Differences in day-23 tumor volume were determined by the Tukey test (*P<0.05, **P<0.01). (B) mRNA was isolated from the tumor on day 26. Expression data were normalized to Gapdh expression and are shown as the mean ± S.E.M. of each group (n=6/group). Differences were determined by the Dunnett test (**P<0.01). (C) TILs were isolated from tumors on day 26. The frequency of effector memory T cells in the CD8+ T cell population was analyzed by flow cytometry. Effector memory T cells were defined as CD62L-CD127+ cells in the CD8+ T gate. The value is the mean ± S.E.M. Differences were determined by the Tukey multiple comparison test (*P<0.05). (D) 4T1 tumors were inoculated subcutaneously into the dorsal flanks of Balb/c mice on day 0. 5 mg/kg of DSP-0509 was administered intravenously on days 5, 12, and 21. 200 μg/mouse of anti-CTLA4 antibody (9F10) was administered intraperitoneally on days 5, 8, 12, 15, and 19. Tumor volume is the mean ± S.E.M of each group (n=6/group). Differences in the day-19 tumor volume were determined by the Dunnett test (*P<0.05).